| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
20,415 |
16,168 |
$1.36M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
25,562 |
19,700 |
$1.32M |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
9,915 |
7,840 |
$1.03M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
12,477 |
9,521 |
$420K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
3,572 |
2,960 |
$238K |
| 99199 |
Unlisted special service, procedure or report |
23,428 |
13,038 |
$158K |
| 99406 |
|
17,781 |
13,467 |
$125K |
| 83970 |
|
2,026 |
1,703 |
$89K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
2,112 |
1,774 |
$67K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
557 |
427 |
$47K |
| 81025 |
|
6,733 |
5,394 |
$41K |
| 99215 |
Prolong outpt/office vis |
483 |
441 |
$40K |
| 80053 |
Comprehensive metabolic panel |
2,684 |
2,364 |
$25K |
| 86769 |
|
656 |
557 |
$24K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
2,664 |
2,329 |
$22K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,281 |
1,323 |
$21K |
| 94375 |
|
1,042 |
828 |
$17K |
| 80061 |
Lipid panel |
1,200 |
1,026 |
$16K |
| 83735 |
|
1,946 |
1,640 |
$14K |
| 80074 |
|
226 |
218 |
$13K |
| 84480 |
|
822 |
697 |
$12K |
| 36415 |
Collection of venous blood by venipuncture |
6,042 |
4,943 |
$9K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
799 |
693 |
$8K |
| 84439 |
|
810 |
686 |
$8K |
| 84443 |
Thyroid stimulating hormone (TSH) |
440 |
403 |
$8K |
| 82607 |
|
325 |
276 |
$5K |
| 72100 |
|
269 |
215 |
$4K |
| 93000 |
|
327 |
277 |
$4K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
60 |
44 |
$3K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
93 |
81 |
$3K |
| 99443 |
|
55 |
37 |
$3K |
| 90756 |
|
193 |
151 |
$2K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
42 |
31 |
$2K |
| 99442 |
|
66 |
46 |
$2K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
60 |
45 |
$2K |
| 99205 |
Prolong outpt/office vis |
14 |
14 |
$2K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
225 |
186 |
$1K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
60 |
44 |
$1K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
41 |
36 |
$1K |
| 86703 |
|
68 |
61 |
$871.37 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
253 |
215 |
$807.10 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
25 |
24 |
$446.26 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
632 |
485 |
$417.70 |
| 71046 |
Radiologic examination, chest; 2 views |
21 |
12 |
$277.12 |
| 84550 |
|
44 |
37 |
$236.77 |
| 86431 |
|
33 |
26 |
$227.85 |
| 81002 |
|
308 |
240 |
$183.97 |
| 90688 |
|
15 |
14 |
$163.97 |
| 82962 |
|
84 |
65 |
$163.89 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
413 |
349 |
$137.42 |
| 80050 |
General health panel |
14 |
12 |
$125.18 |
| 99497 |
|
114 |
96 |
$95.27 |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
15 |
14 |
$59.19 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
19 |
12 |
$53.32 |
| 1159F |
|
228 |
171 |
$6.47 |
| G0442 |
Annual alcohol misuse screening, 5 to 15 minutes |
678 |
541 |
$2.24 |
| 1125F |
|
424 |
358 |
$0.01 |
| 3078F |
|
5,634 |
5,035 |
$0.00 |
| 4004F |
|
823 |
718 |
$0.00 |
| 3077F |
|
1,113 |
1,001 |
$0.00 |
| G0446 |
Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes |
130 |
106 |
$0.00 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
127 |
96 |
$0.00 |
| 3074F |
|
6,128 |
5,445 |
$0.00 |
| 3044F |
|
94 |
87 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
61 |
45 |
$0.00 |
| 3080F |
|
215 |
198 |
$0.00 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
272 |
220 |
$0.00 |
| 3008F |
|
14,815 |
12,798 |
$0.00 |
| 3079F |
|
2,875 |
2,612 |
$0.00 |
| 3075F |
|
1,031 |
963 |
$0.00 |
| 3048F |
|
30 |
27 |
$0.00 |
| 4010F |
|
14 |
14 |
$0.00 |
| 1170F |
|
52 |
43 |
$0.00 |
| G8839 |
Sleep apnea symptoms assessed, including presence or absence of snoring and daytime sleepiness |
14 |
14 |
$0.00 |